The Effect of Neoadjuvant Chemotherapy on Bleeding Rate and Length of Surgery in Breast Surgeries: a Systematic Review and Meta-Analysis

Neoadjuvant chemotherapy may increase complications after surgery, the incidence of these complications has not been accurately reported; Among these complications, we can mention the duration of surgery and the amount of bleeding during surgery, which are associated with subsequent complications, and there is no accurate information in this field; Therefore, the present study was conducted with the aim of investigating the effect of neoadjuvant chemotherapy on the amount of bleeding and length of surgery in breast surgeries in the form of a meta-analysis.

This study was conducted as a meta-analysis during 2022; A search using MEDLINE, Embase, the Cochrane Library, Google Scholar, ClinicalTrials.gov and the WHO International Clinical Trials Registry platform to identify studies evaluating the effect of neoadjuvant chemotherapy on complications after breast surgery with the keywords breast cancer/breast neoplasm; neoadjuvant therapy/neoadjuvant chemotherapy; Breast surgery/mastectomy was performed in this systematic review and meta-analysis.

Neoadjuvant treatment insignificantly reduces the duration of surgery (95% CI = -22.42-27.76, MD = 2.67, P = 0.083, I2 = 99%); Also, neoadjuvant treatment significantly reduces bleeding during surgery (95% CI = -107.44-23, MD = -75.85, P = 0.0001, I = 97%) (Figure 1, part B); It should be noted that the heterogeneity of both studies was significantly high.

Neoadjuvant chemotherapy with a partial face leads to an increase in the length of the surgical period and significantly leads to a decrease in the amount of bleeding during breast surgery.